Activation of MEK/erk pathway can upregulate B7H4, and activation of PI3K/Akt can upregulate PD-L1, suggesting that MEK/erk and PI3K/Akt signaling pathways are involved in EGFR mutation-positive lung cancer (72). Here, EGFR is linked to lung carcinoma.